TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07120503: Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Sponsor: Windward Bio · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT07120503 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07120503 Rescue Dossier →